DIRS.INFO The most relevant business & tech news

☆ We're overhauling our Bullpen watchlist — 3 stocks are gone, the rest stick around
▼ + stars: | 2024-11-15 | by ( Paulina Likos | ) www.cnbc.com time to read: +4 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. A view of the New York Stock Exchange (NYSE) on Wall Street November 13, 2024, in New York City.

Persons: Jim Cramer, Jim, Brian Chesky, Trump, Marvell, Jim chalked, Matt Murphy's, we're, hasn't, Amgen's, it's, Jim Cramer's, Angela Weiss Organizations: Pepsico, RTX, Marvell Technology, Nvidia, AMD, Broadcom, Novartis, JPMorgan Healthcare, Dow Inc, Jim Cramer's Charitable, CNBC, New York Stock Exchange, AFP, Getty Locations: RTX, Russia, Ukraine, Swiss, China, New York City

☆ GEHC stock finally gets some respect after earnings. Those betting against it got slammed
▼ + stars: | 2024-02-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +8 min

Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. The quarterly earnings result from GE Healthcare on Tuesday is the best of both worlds. Quarterly commentary In addition to the mid-single-digit organic revenue growth, total company orders increased by 3%. The continued divergence in orders between the two companies suggests GE HealthCare is taking market share in the industry. A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

Persons: Eli Lilly, GEHC, It's, Jim Cramer, Philips, we're, GEHC's, We're, Jim Cramer's, Jim Organizations: GE Healthcare Technologies, The, Starbucks, GE Healthcare, General Electric, GE HealthCare, Management, JPMorgan Healthcare, Federal Reserve, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: China, ultrasounds, MRIs, New York

We're selling 95 shares of GE Healthcare at roughly $74. Following Wednesday's trade, Jim Cramer's Charitable Trust will own 1,150 shares of GEHC, reducing its weighting to 2.75% from 2.97%. If hospitals have more of a wherewithal to invest in medical equipment, some of that will go to GE Healthcare. Philips orders have been down for six quarters in a row, but GE Healthcare hasn't seen that weakness yet. With Wednesday's sale, we'll realize a small loss of about 7% on GEHC stock purchased last May.

Persons: Jim Cramer's, GEHC, We've, Jim Cramer, Jim Organizations: GE Healthcare, JPMorgan Healthcare, Philips, GE, JPMorgan, GE Healthcare hasn't, CNBC Locations: China, GEHC

☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
▼ + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.

Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid

☆ Jim Cramer says it's 'totally the wrong time to sell' this life sciences stock on a roll
▼ + stars: | 2024-01-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch audio feature in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Estee Lauder, It's, LVMH, Jefferies, Peltz, Abbott, ABT, Morgan Stanley, Wynn, Brown Forman, Sartorius, Jim, Jim Cramer's Organizations: CNBC, Meta, Disney, DuPont, Constellation Brands, JPMorgan, Jim Cramer's Charitable Locations: German

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ Here's what I'm watching to see where the market goes next after the S&P 500 record close
▼ + stars: | 2024-01-21 | by ( Jim Cramer | ) www.cnbc.com time to read: +10 min

We don't know what we want. The rails are too significant to ignore even as the bond market seems to rely, I would say, wrongly, on the broader data. I think it's a factor of big money flows that aren't sensitive to what moves rates and don't mind being wrong. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Tesla, ServiceNow, Bill McDermott, Russell, —, Abbott, Gamble, Jon Moeller, Heels, what's, hasn't, Steve Jobs, Ray, Kimberly, Clark, Jim Cramer's, Jim Cramer, Jim, Virginia Sherwood Organizations: Union Pacific, CSX, Norfolk Southern, Federal Reserve, Silicon Valley Bank, Microsoft, Nvidia tacking, Google, Apple, Nvidia, JPMorgan Healthcare Conference, Abbott Laboratories, Investing, JPMorgan, Novartis, Walgreens Boots Alliance, Procter, Super, YouTube, Netflix, Vision, Pro, Jim Cramer's Charitable, CNBC, NYSE Locations: U.S, Silicon, San Francisco, Amgen, China

☆ Why we like health-care stocks in 2024 despite their spotty record in presidential election years
▼ + stars: | 2024-01-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

The S & P 500 Health Care Sector index has outperformed the broader S & P 500 in just three of the past eight presidential election years dating back to 1992, according to FactSet data. So far in 2024, health care has been the best-performing sector in the S & P 500, climbing roughly 2%. .GSPHC .SPX YTD mountain Health care sector vs. S & P 500 YTD It's way too early for any grand predictions with Election Day 2024 about 10 months away. Nevertheless, we see attractive fundamentals in the year ahead for a host of health-care stocks, giving us the confidence to own Lilly, GE Healthcare and Danaher despite what history says about the group in presidential election years. After a strong 2022 for health care in a terrible overall market, investors last year placed a lower emphasis on the defensive characteristics of health care.

Persons: —, that's, Eli Lilly, Lilly, Jim Cramer, Jim, Sen, Bernie Sanders of, Joe Biden, Sanders, would've, Damien Conover, Conover, Biden, Eli Lilly's, Morningstar, Amgen, Morningstar's Conover, Lilly's donanemab, Humana, Bausch, Jim Cramer's, Frederick Florin Organizations: Health, GE Healthcare, Abbott Laboratories, Amgen, Novartis, Walgreens Boots Alliance, JPMorgan Healthcare Conference, Democratic, Morningstar, CNBC, Horizon Therapeutics, Novo Nordisk, Federal Reserve, General Electric, Medicare, Humana, UnitedHealth Group, Investors, AFP, Getty Locations: San Francisco, U.S, Bernie Sanders of Vermont, Canadian, Fegersheim, France

☆ The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
▼ + stars: | 2024-01-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Michael Siluk | UCG | Getty ImagesBoehringer IngelheimBoehringer Ingelheim is developing a weight loss drug with Danish biotech firm Zealand Pharma. Some popular weight loss drugs such as Novo Nordisk's Wegovy only target GLP-1. Terns PharmaceuticalsSmaller drugmakers are developing their own weight loss drugs. Quirk acknowledged that it may be difficult for Terns to set its pill apart from other weight loss drugs. Viking Therapeutics expects to release mid-stage trial data on its weight loss injection in the first half of the year.

Persons: Michael Siluk, Boehringer Ingelheim, Erin Quirk, Quirk, it's, Eli Lilly's, Roger Song Organizations: UCG, Getty, Zealand Pharma, Nordisk's, Drug Administration, JPMorgan Healthcare Conference, Pharmaceuticals, Terns Pharmaceuticals, GLP, Viking Therapeutics, Therapeutics, Jefferies Locations: Viking

☆ Cramer likes this health care stock that has corrected but whose fundamentals are improving
▼ + stars: | 2024-01-16 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch audio feature in time for the last hour of trading on Wall Street. Jim Cramer said is looking for stocks that have fallen after a big run but whose fundamentals are improving, like GE Healthcare . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Christopher Waller, Ruth Porat, Morgan Stanley, Danaher, Estee Lauder, Jim Cramer's, Jim Organizations: CNBC, Fed, Bloomberg, GE Healthcare, Nvidia, Palo, Disney, ESPN, NFL, JPMorgan Healthcare, Bank, DuPont, Bank of America, Jim Cramer's Charitable Locations: Davos, Palo Alto

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
▼ + stars: | 2024-01-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. Interest in the drugs will only continue this year, as some analysts expect more dealmaking and advancements in ADCs currently in development. The drugs also have potential to draw huge profits: ADCs could account for $31 billion of the $375 billion worldwide cancer market in 2028, according to estimates from the drug market research firm Evaluate. The market for those drugs in 2023 was estimated to be worth around $9.7 billion, another report from research firm MarketsandMarkets said. Everyone wants to gain exposure to [ADCs] and basically make it a cornerstone of their entire corporate strategy," Hsieh told CNBC.

Persons: FRANCISCO —, Johnson, Andy Hsieh, William Blair, MarketsandMarkets, Hsieh Organizations: FRANCISCO, JPMorgan Healthcare Conference, ADC, Pfizer, Merck, William Blair & Company, CNBC Locations: San Francisco, ADCs, drugmakers, Asia

☆ What's old is new: Our 3 best stocks to start 2024 were also big winners last year
▼ + stars: | 2024-01-12 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

Artificial intelligence chipmaker Nvidia , cybersecurity provider Palo Alto Networks and pharma giant Eli Lilly are the Club's biggest gainers to start 2024. Palo Alto Networks, meanwhile, jumped nearly 112% last year, becoming the first cybersecurity company to reach a $100 billion market capitalization . LLY 3M mountain Eli Lilly 3 months Eli Lilly has been positive in six of the eight trading days in 2024, including Thursday's session . PANW 3M mountain Palo Alto Networks 3 months Shares of Palo Alto Networks began 2024 on a rough note, falling in each of the first four trading days amid a larger seven-session skid that stretched into December. Wednesday's advance came after Morgan Stanley hiked its Palo Alto price target to $375 per share from $304.

Persons: haven't, Eli Lilly, Wall, hasn't, Eli Lilly's, Oppenheimer, Lilly, Morgan Stanley, Jim Cramer's, Jim Cramer, Jim Organizations: Nvidia, Palo Alto Networks, pharma, Club, Palo, Consumer, Semiconductor, Mizuho, Truist, Bank of America, JPMorgan Healthcare Conference, CNBC, New York Stock Exchange, Bloomberg, Getty Locations: Palo Alto, Las Vegas, New York, U.S

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

☆ What's next for Goldman following deep cuts and organization overhaul
▼ + stars: | 2023-01-17 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +5 min

On tap we've got stories on JPMorgan's Jamie Dimon fielding questions about the bank's acquisition strategy, another bank plans to make cuts, and fast food options that won't completely crush your diet. On Wednesday the bank conducted a majority of its cuts, reducing its global workforce by about 6.5%. A few days later, on Friday, the bank reported losses of more than $3 billion since 2020 in the unit that houses the bank's consumer lending business. Meanwhile, some of the recently axed Goldman employees have been left in the dark on what's next for them, according to reporting from Hayley and Emmalyse Brownstein. Here are some fast food options that won't completely wreck your diet.

☆ Novartis' CEO is charging ahead in cutting tens of thousands of workers to transform the $220 billion pharma giant
▼ + stars: | 2023-01-16 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +3 min

Novartis is laying off thousands of workers, CEO Vasant Narasimhan told Insider. Through layoffs and spinoffs, the Swiss giant expects to trim its headcount by about 30% by 2024. SAN FRANCISCO — Thousands of layoffs are "happening now," Vasant Narasimhan, the CEO of Novartis, told Insider, as he hopes the $220 billion Swiss giant is entering the final steps of becoming a smaller, more-focused drug company. The Swiss giant had about 125,000 full-time employees at the time, and it has about 108,000 workers today. The restructuring will save Novartis about $1.5 billion annually, Narasimhan said during his Monday presentation at the JPMorgan conference.

☆ Stocks making the biggest moves midday: Bed Bath & Beyond, Tesla, Expedia and more
▼ + stars: | 2023-01-11 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Meme stocks — A group of so-called meme stocks skyrocketed Wednesday as retail investors jumped into speculative trades again. Bed Bath & Beyond rallied 38% to trigger the trend in morning trading Wednesday. Expedia — The travel company's stock gained more than 4% after Oppenheimer upgraded it to outperform from perform. The Wall Street firm said it believes Expedia shares are discounting macro headwinds. Toll Brothers — The homebuilding stock gained 3% following an upgrade to a buy from a hold rating by analysts at Bank of America.

☆ 2 of our stocks get nice pops. Here's the news and what we think
▼ + stars: | 2023-01-10 | by ( Zev Fima | ) www.cnbc.com time to read: +6 min

DHR 1Y mountain Danaher's 1 year stock performance Danaher is set to present at the JPMorgan Healthcare Conference on Tuesday afternoon. Now, management sees core sales growth up in the high single-digit range. In addition to the core revenue growth revision, management is now factoring in no growth coming from Covid-related testing. STZ 1Y mountain Constellation Brands 1-year stock performance;. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Search resuls for: "JPMorgan Healthcare"

18 mentions found